<DOC>
	<DOCNO>NCT02846532</DOCNO>
	<brief_summary>The Purpose study characterize single multiple-dose pharmacokinetic ( PK ) pharmacokinetic/pharmacodynamic ( PK/ PD ) profile oral rivaroxaban therapy administer pediatric participant 2 8 year age single ventricle physiology complete Fontan procedure within 4 month prior enrollment ( Part A ) evaluate safety efficacy rivaroxaban , administer twice daily ( exposure match rivaroxaban 10 milligram [ mg ] daily adult ) compare acetylsalicylic acid ( ASA ) , give daily ( approximately 5 milligram per kilogram [ mg/kg ] ) thromboprophylaxis pediatric participant 2 8 year age single ventricle physiology complete Fontan procedure within 4 month prior enrollment .</brief_summary>
	<brief_title>Pharmacokinetic , Pharmacodynamic , Safety , Efficacy Study Rivaroxaban Thromboprophylaxis Pediatric Participants 2 8 Years Age After Fontan Procedure</brief_title>
	<detailed_description>Part A : This part include 12-day Initial PK , PD , Safety Assessment Period . Participants Part A participate Part B. Randomization Part B study begin cumulative data Initial PK , PD , Safety Assessment Period Part A deem acceptable Independent Data Monitoring Committee . Part A study consist 21-day Screening Period , 12-day Initial PK , PD , Safety Assessment Period , 12-month Open-Label Treatment Period , 30-day Follow-Up phone contact . Part B : Participants randomly assign two treatment group randomization ratio 2:1 rivaroxaban ASA . ASA use control . There 21-day Screening Period , 12 month Open-Label Treatment Period 30-day Follow-Up phone contact .</detailed_description>
	<mesh_term>Thrombosis</mesh_term>
	<mesh_term>Aspirin</mesh_term>
	<mesh_term>Rivaroxaban</mesh_term>
	<criteria>Participant must consider clinically stable investigator able tolerate oral enteral administration suspension formulation oral/enteral feeding Satisfactory initial postFontan transthoracic echocardiographic Screening define PostFontan Echocardiographic Examination Research Protocol Parent/legally acceptable representative must sign informed consent form ( ICF ) child assent also provide , applicable , accord local requirement Evidence thrombosis , include asymptomatic confirm postFontan procedure transthoracic echocardiogram , image technique , Screening period study History gastrointestinal disease surgery associate clinically relevant impaired absorption History signs/symptoms suggestive proteinlosing enteropathy Active bleeding high risk bleed contraindicate antiplatelet anticoagulant therapy , include history intracranial bleeding Platelet count le ( &lt; ) 50*10^9/Liters ( L ) Screening Creatinine clearance ( CrCl ) &lt; 30 milliliter per minute per 1.73 meter square ( mL/min/1.73m^2 ) Known clinically significant liver disease</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>8 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Thromboembolism</keyword>
	<keyword>Fontan Procedure</keyword>
	<keyword>Children</keyword>
</DOC>